TY - JOUR
T1 - Percutaneous radiofrequency ablation for patients with malignant lung tumors
T2 - a phase II prospective multicenter study (JIVROSG-0702)
AU - Gobara, Hideo
AU - Arai, Yasuaki
AU - Kobayashi, Takeshi
AU - Yamakado, Koichiro
AU - Inaba, Yoshitaka
AU - Kodama, Yoshihisa
AU - Yamagami, Takuji
AU - Sone, Miyuki
AU - Watanabe, Hirokazu
AU - Okumura, Yoshihiro
AU - Shinya, Takayoshi
AU - Kurihara, Hiroaki
AU - Kanazawa, Susumu
N1 - Funding Information:
This study was supported by a Grant-in-Aid for a comprehensive research project on the practical application of medical technology from the Japanese Ministry of Health, Labour, and Welfare.
Publisher Copyright:
© 2016, Japan Radiological Society.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Purpose: This prospective multicenter study aimed to evaluate the efficacy and safety of percutaneous radiofrequency (RF) ablation for lung cancer. Materials and methods: From May 2008 to April 2012, 33 patients (26 men, 7 women; mean age 70.5 years) were enrolled. RF ablation was performed using an internally cooled or expandable multitined electrode. The primary endpoint was complete response (CR) determined using 18F fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) performed 6 months after RF ablation. The secondary endpoint was the incidence and grade of adverse events (AEs) evaluated using the Common Toxicity Criteria for Adverse Events, version 3.0. Results: All patients underwent RF ablation and had efficacy analyses evaluated; however, FDG-PET/CT images before RF ablation were not available for two patients. The CR rate was 68 % (21 of 31 patients). One patient had a grade 5 AE unrelated to RF ablation. Grade ≥3 AEs occurred in 12 % of patients. During the follow-up period (median 37 months; range 1–55 months), five patients developed local tumor progression and nine (29 %) died. Overall survival at 1, 2, and 3 years was 97, 82, and 74 %, respectively. Conclusion: Percutaneous RF ablation is a safe, feasible, and effective treatment for small malignant lung tumors.
AB - Purpose: This prospective multicenter study aimed to evaluate the efficacy and safety of percutaneous radiofrequency (RF) ablation for lung cancer. Materials and methods: From May 2008 to April 2012, 33 patients (26 men, 7 women; mean age 70.5 years) were enrolled. RF ablation was performed using an internally cooled or expandable multitined electrode. The primary endpoint was complete response (CR) determined using 18F fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) performed 6 months after RF ablation. The secondary endpoint was the incidence and grade of adverse events (AEs) evaluated using the Common Toxicity Criteria for Adverse Events, version 3.0. Results: All patients underwent RF ablation and had efficacy analyses evaluated; however, FDG-PET/CT images before RF ablation were not available for two patients. The CR rate was 68 % (21 of 31 patients). One patient had a grade 5 AE unrelated to RF ablation. Grade ≥3 AEs occurred in 12 % of patients. During the follow-up period (median 37 months; range 1–55 months), five patients developed local tumor progression and nine (29 %) died. Overall survival at 1, 2, and 3 years was 97, 82, and 74 %, respectively. Conclusion: Percutaneous RF ablation is a safe, feasible, and effective treatment for small malignant lung tumors.
KW - Clinical trial
KW - JIVROSG
KW - Lung cancer
KW - Multicenter
KW - Prospective
KW - Radiofrequency ablation
UR - http://www.scopus.com/inward/record.url?scp=84980316441&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84980316441&partnerID=8YFLogxK
U2 - 10.1007/s11604-016-0557-z
DO - 10.1007/s11604-016-0557-z
M3 - Article
C2 - 27260478
AN - SCOPUS:84980316441
SN - 1867-1071
VL - 34
SP - 556
EP - 563
JO - Japanese Journal of Radiology
JF - Japanese Journal of Radiology
IS - 8
ER -
